Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (2r)-2-amino-3-phenylpropyl Carbamate
2. (r)-2-amino-3-phenylpropylcarbamate Hydrochloride
3. Adx-n05
4. Benzenepropanol, Beta-amino-, Carbamate (ester), (betar)-
5. Jzp-110
6. Solriamfetol
7. Sunosi
1. Jzp-110 Hydrochloride
2. 178429-65-7
3. Solriamfetol (hydrochloride)
4. K7ro88sp7a
5. Solriamfetol Hydrochloride [usan]
6. Solriamfetol Hydrochloride (usan)
7. R-228060
8. Sunosi (tn)
9. Unii-k7ro88sp7a
10. Adx-n05 Hydrochloride
11. Ykp-10a Hydrochloride
12. Schembl8430382
13. Adx-n-05 Hydrochloride
14. Skl-n-05 Hydrochloride
15. Chembl4297212
16. Dtxsid101027927
17. R-228060 Hydrochloride
18. Hy-109043a
19. Solriamfetol Hydrochloride [mi]
20. Solriamfetol Hydrochloride [who-dd]
21. Cs-0112102
22. O-carbamoyl-(d)-phenylalaninol Hydrochloride
23. D11328
24. Solriamfetol Hydrochloride [orange Book]
25. (d)-o-carbamoylphenylalaninol Hydrochloride Salt
26. R228060;jzp-110;adx-n05;skl-n05;ykp-10
27. (2r)-2-amino-3-phenylpropyl Carbamate, Monohydrochloride
28. (betar)-beta-amino-benzenepropanol 1-carbamate Hydrochloride (1:1)
29. (r)-(+)-2-amino-1-carbamoyloxy-3-phenylpropane Hydrochloride
30. Benzenepropanol, .beta.-amino-, 1-carbamate, Hydrochloride (1:1), (.beta.r)-
31. 561069-23-6
Molecular Weight | 230.69 g/mol |
---|---|
Molecular Formula | C10H15ClN2O2 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 230.0822054 g/mol |
Monoisotopic Mass | 230.0822054 g/mol |
Topological Polar Surface Area | 78.3 Ų |
Heavy Atom Count | 15 |
Formal Charge | 0 |
Complexity | 179 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).
Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).
N06BA14
GDUFA
DMF Review : Complete
Rev. Date : 2022-12-16
Pay. Date : 2022-11-14
DMF Number : 34741
Submission : 2020-03-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-02-15
Pay. Date : 2023-02-03
DMF Number : 36951
Submission : 2022-03-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-04-28
Pay. Date : 2023-01-09
DMF Number : 37929
Submission : 2023-01-10
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-05-16
Pay. Date : 2023-04-12
DMF Number : 38280
Submission : 2023-04-18
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-04-04
Pay. Date : 2022-12-19
DMF Number : 37548
Submission : 2022-12-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-03-16
Pay. Date : 2023-01-25
DMF Number : 36949
Submission : 2022-03-30
Status : Active
Type : II
About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...
About the Company : Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not on...
About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...
About the Company : Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in mark...
Details:
Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for major depressive disorder (MDD) with and without severe excessive daytime sleepiness.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2025
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Reports PARADIGM Ph 3 Results Of Solriamfetol in MDD wth/without EDS
Details : Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for major depressive disorder (MDD) with and without severe excessive daytime sleepiness.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 01, 2025
Details:
Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for the treatment of attention deficit hyperactivity disorder.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2025
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome’s Phase 3 FOCUS Trial of Solriamfetol in ADHD Meets Endpoint
Details : Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is being evaluated for the treatment of attention deficit hyperactivity disorder.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 25, 2025
Details:
Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Sleep Brand Name: Sunosi
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 29, 2024
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Highlights Data on Solriamfetol Showing Cognitive Improvement in Narcolepsy
Details : Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 29, 2024
Details:
Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of major depressive disorder.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2024
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Initiates PARADIGM Phase 3 Of Solriamfetol For Major Depressive Disorder Treatment
Details : Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of major depressive disorder.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 19, 2024
Details:
Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of binge eating disorder.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 04, 2024
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Initiates ENGAGE Phase 3 Trial of Solriamfetol for Binge Eating Disorder
Details : Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of binge eating disorder.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 04, 2024
Details:
Sunosi (solriamfetol), is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with Attention Deficit Hyperactivity Disorder (ADHD) in Adults.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Sunosi
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 07, 2023
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sunosi (solriamfetol), is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with Attention Deficit Hyperactivity Disorder (ADHD) in Adults.
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 07, 2023
Details:
Under the agreement, Pharmanovia will be responsible for the development and marketing of Sunosi (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults with EDS due to narcolepsy or OSA, in Europe and MENA regions.
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Sleep Brand Name: Sunosi
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Pharmanovia
Deal Size: $167.0 million Upfront Cash: $66.0 million
Deal Type: Licensing Agreement February 22, 2023
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pharmanovia
Deal Size : $167.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Pharmanovia will be responsible for the development and marketing of Sunosi (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults with EDS due to narcolepsy or OSA, in Eur...
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : $66.0 million
February 22, 2023
Details:
Sunosi (solriamfetol), is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Sleep Brand Name: Sunosi
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Axsome Therapeutics
Deal Size: Undisclosed Upfront Cash: $53.0 million
Deal Type: Divestment September 05, 2022
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Axsome Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics
Details : Sunosi (solriamfetol), is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : $53.0 million
September 05, 2022
Details:
Sunosi (solriamfetol) is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Sleep Brand Name: Sunosi
Study Phase: Phase IVProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 09, 2022
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Day...
Details : Sunosi (solriamfetol) is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 09, 2022
Details:
Sunosi (solriamfetol) is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
Lead Product(s): Solriamfetol Hydrochloride
Therapeutic Area: Sleep Brand Name: Sunosi
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 28, 2022
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
Details : Sunosi (solriamfetol) is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
Product Name : Sunosi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 28, 2022
RLD : Yes
TE Code :
Brand Name : SUNOSI
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 75MG BASE
Approval Date : 2019-06-17
Application Number : 211230
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : SUNOSI
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 150MG BASE
Approval Date : 2019-06-17
Application Number : 211230
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD :
TE Code :
Brand Name : SOLRIAMFETOL
Dosage Form : TABLET
Dosage Strength : 300MG
Approval Date :
Application Number : 218654
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SOLRIAMFETOL
Dosage Form : TABLET
Dosage Strength : 75MG
Approval Date :
Application Number : 218654
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SOLRIAMFETOL
Dosage Form : TABLET
Dosage Strength : 150MG
Approval Date :
Application Number : 218654
RX/OTC/DISCN :
RLD :
TE Code :
Regulatory Info :
Registration Country : Norway
Brand Name : Sunosi
Dosage Form : Tablet, film-coated
Dosage Strength : 75 mg
Packaging : Blisterpakning 28item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Sunosi
Dosage Form : Tablet, film-coated
Dosage Strength : 150 mg
Packaging : Blisterpakning 28item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
02 Apr 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/axsomes-depression-treatment-fails-meet-main-goal-late-stage-study-2025-04-01/
26 Mar 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/axsome-touts-success-phase-3-trial-sunosi-adhd
05 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/05/3037271/33090/en/Axsome-Therapeutics-Settles-Sunosi-solriamfetol-Patent-Litigation-with-Hikma-Pharmaceuticals-USA.html
24 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/24/2952012/33090/en/Axsome-Therapeutics-Presents-Data-from-Multiple-Programs-at-Sleep-Europe-2024.html
21 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/21/2933398/33090/en/Axsome-Therapeutics-Reaches-Agreement-to-Dismiss-Sunosi-Solriamfetol-Patent-Litigation-with-Sandoz-Inc.html
01 Apr 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/04/01/2855085/33090/en/Axsome-Therapeutics-Initiates-ENGAGE-Phase-3-Trial-of-Solriamfetol-for-the-Treatment-of-Binge-Eating-Disorder.html
Global Sales Information
Dosage Form : Tablet, film-coated
Dosage Strength : 75 mg
Price Per Pack (Euro) : 191.06
Published in :
Country : Norway
RX/OTC/DISCN :
Dosage Form : Tablet, film-coated
Dosage Strength : 150 mg
Price Per Pack (Euro) : 263.56
Published in :
Country : Norway
RX/OTC/DISCN :
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 28
2019 Revenue in Millions : 4
Growth (%) : 663
Main Therapeutic Indication : Sleep
Currency : USD
2021 Revenue in Millions : 58
2020 Revenue in Millions : 28
Growth (%) : 104
Main Therapeutic Indication : Sleep
Currency : USD
2022 Revenue in Millions : 29
2021 Revenue in Millions : 58
Growth (%) : -50
Main Therapeutic Indication : Sleep
Currency : USD
2023 Revenue in Millions : 0
2022 Revenue in Millions : 29
Growth (%) : Divested to Axsome
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 4
2018 Revenue in Millions : 0
Growth (%) : New launch
Market Place
Reply
30 Aug 2022
Reply
12 Oct 2019
Patents & EXCLUSIVITIES
Patent Expiration Date : 2031-06-11
US Patent Number : 8440715
Drug Substance Claim :
Drug Product Claim :
Application Number : 211230
Patent Use Code : U-2548
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2031-06-11
Patent Expiration Date : 2042-12-30
US Patent Number : 12036194
Drug Substance Claim :
Drug Product Claim :
Application Number : 211230
Patent Use Code : U-3693
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2042-12-30
Patent Expiration Date : 2042-12-30
US Patent Number : 12102609
Drug Substance Claim :
Drug Product Claim :
Application Number : 211230
Patent Use Code : U-3693
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2042-12-30
Patent Expiration Date : 2042-12-30
US Patent Number : 11771667
Drug Substance Claim :
Drug Product Claim :
Application Number : 211230
Patent Use Code : U-3693
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2042-12-30
Patent Expiration Date : 2042-12-30
US Patent Number : 11872204
Drug Substance Claim :
Drug Product Claim :
Application Number : 211230
Patent Use Code : U-3693
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2042-12-30
Patent Expiration Date : 2037-09-05
US Patent Number : 11998639
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 211230
Patent Use Code : U-2548
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2037-09-05
Patent Expiration Date : 2040-03-19
US Patent Number : 11850227
Drug Substance Claim :
Drug Product Claim :
Application Number : 211230
Patent Use Code : U-3775
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2040-03-19
Patent Expiration Date : 2040-03-19
US Patent Number : 11160779
Drug Substance Claim :
Drug Product Claim :
Application Number : 211230
Patent Use Code : U-3521
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2040-03-19
Patent Expiration Date : 2038-06-01
US Patent Number : 11865098
Drug Substance Claim :
Drug Product Claim :
Application Number : 211230
Patent Use Code : U-2548
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-06-01
Patent Expiration Date : 2026-06-07
US Patent Number : 10351517
Drug Substance Claim :
Drug Product Claim :
Application Number : 211230
Patent Use Code : U-2548
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-06-07
Exclusivity Code : ODE-254
Exclusivity Expiration Date : 2026-06-17
Application Number : 211230
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-254
Exclusivity Expiration Date : 2026-06-17
Application Number : 211230
Product Number : 2
Exclusivity Details :
ABOUT THIS PAGE
74
PharmaCompass offers a list of Solriamfetol Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Solriamfetol Hydrochloride manufacturer or Solriamfetol Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Solriamfetol Hydrochloride manufacturer or Solriamfetol Hydrochloride supplier.
PharmaCompass also assists you with knowing the Solriamfetol Hydrochloride API Price utilized in the formulation of products. Solriamfetol Hydrochloride API Price is not always fixed or binding as the Solriamfetol Hydrochloride Price is obtained through a variety of data sources. The Solriamfetol Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A JZP-110 hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of JZP-110 hydrochloride, including repackagers and relabelers. The FDA regulates JZP-110 hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. JZP-110 hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of JZP-110 hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A JZP-110 hydrochloride supplier is an individual or a company that provides JZP-110 hydrochloride active pharmaceutical ingredient (API) or JZP-110 hydrochloride finished formulations upon request. The JZP-110 hydrochloride suppliers may include JZP-110 hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of JZP-110 hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A JZP-110 hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of JZP-110 hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of JZP-110 hydrochloride DMFs exist exist since differing nations have different regulations, such as JZP-110 hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A JZP-110 hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. JZP-110 hydrochloride USDMF includes data on JZP-110 hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The JZP-110 hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of JZP-110 hydrochloride suppliers with USDMF on PharmaCompass.
A JZP-110 hydrochloride written confirmation (JZP-110 hydrochloride WC) is an official document issued by a regulatory agency to a JZP-110 hydrochloride manufacturer, verifying that the manufacturing facility of a JZP-110 hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting JZP-110 hydrochloride APIs or JZP-110 hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a JZP-110 hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of JZP-110 hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing JZP-110 hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for JZP-110 hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture JZP-110 hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain JZP-110 hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a JZP-110 hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of JZP-110 hydrochloride suppliers with NDC on PharmaCompass.
JZP-110 hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of JZP-110 hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right JZP-110 hydrochloride GMP manufacturer or JZP-110 hydrochloride GMP API supplier for your needs.
A JZP-110 hydrochloride CoA (Certificate of Analysis) is a formal document that attests to JZP-110 hydrochloride's compliance with JZP-110 hydrochloride specifications and serves as a tool for batch-level quality control.
JZP-110 hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each JZP-110 hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
JZP-110 hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (JZP-110 hydrochloride EP), JZP-110 hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (JZP-110 hydrochloride USP).